Abbonarsi

Impact of diabetes mellitus on mortality rates and outcomes in myocardial infarction - 12/08/21

Doi : 10.1016/j.diabet.2020.11.003 
Volker H. Schmitt a, c, 1, Lukas Hobohm a, b, 1, Thomas Münzel a, c, Philip Wenzel a, b, c, Tommaso Gori a, b, c, Karsten Keller a, b, d,
a Department of Cardiology, Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany 
b Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany 
c German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, Mainz, Germany 
d Medical Clinic VII, Department of Sports Medicine, University Hospital Heidelberg, Heidelberg, Germany 

Corresponding author at: Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.Department of Cardiology, Cardiology I, University Medical Center Mainz of the Johannes Gutenberg-University MainzLangenbeckstrasse 1Mainz55131Germany

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Highlights

Mortality of diabetes mellitus (DM) patients with myocardial infarction (MI) has decreased over time.
Rates of mortality and recurrent MI are higher in patients with DM.
Older patients with MI are at higher risk of in-hospital death.
MI patients who also have DM have unfavourable cardiovascular profiles.
DM patients are less often treated with cardiac catheterization than non-DM patients.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

Diabetes mellitus (DM) represents a major cardiovascular risk factor for increased risk of coronary artery disease and myocardial infarction (MI). DM is also associated with a poorer clinical outcome in MI.

Materials and methods

The nationwide German inpatient population treated between 2005 and 2016 was used for statistical analyses. Hospitalized MI patients were stratified by the presence of DM and investigated for the impact of DM on in-hospital events.

Results

In total, 3,307,703 hospitalizations for acute MI (37.6% female patients, 56.8% aged ≥ 70 years) treated in Germany during 2005–2016 were included in this analysis. Of these patients, 410,737 (12.4%) died while in hospital. Overall, 1,007,326 (30.5%) MI cases were coded for DM. While the rate of MI patients with DM increased slightly over time, from 29.8% in 2005 to 30.7% in 2016 (β = 7.04, 95% CI: 4.13–9.94; P <  0.001), their in-hospital mortality decreased from 15.2% to 11.5% (β = -0.36, 95% CI: -0.38 to -0.34; P <  0.001). Rates of in-hospital death (13.2% vs 12.1%; P <  0.001) and recurrent MI (0.8% vs 0.6%; P <  0.001) were higher in MI patients with vs without DM. Also, in MI patients with DM, significantly lower use of coronary artery angiography (51.5% vs 56.8%; P <  0.001) and interventional revascularization (37.6% vs 43.9%; P <  0.001) was noted.

Conclusion

Although in-hospital mortality of patients with MI decreased in both diabetes and non-diabetes patients, in-hospital deaths were still higher in diabetes patients, thereby revealing the impact of this metabolic disorder on cardiovascular outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AKI, BMS, BVS, CI, COPD, CAD, CABG, DES, DM, DMP, DRG, DVT, GM, ICD, IQR, MI, OPS, OR, PCI, RDC

Keywords : Diabetes mellitus, Mortality, Myocardial infarction


Mappa


© 2020  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 47 - N° 4

Articolo 101211- luglio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
  • Niels H. Brandt-Jacobsen, Marie Louise Johansen, Jon Rasmussen, Julie L. Forman, Maria Refsgaard Holm, Jens Faber, Patrick Rossignol, Morten Schou, Caroline Kistorp
| Articolo seguente Articolo seguente
  • Glyburide therapy for gestational diabetes: Glycaemic control, maternal hypoglycaemia, and treatment failure
  • Hélène Affres, Marie-Victoire Senat, Alexandra Letourneau, Philippe Deruelle, Magali Coustols-Valat, Hanane Bouchghoul, Jean Bouyer

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.